Abstract: The invention relates to chimeric or humanised anti-CD303 antibodies to nucleic acids coding for the heavy and light chains of these antibodies, expression vectors, host cells, transgenic non-human animals or transgenic plants expressing said antibodies, as well as to the uses thereof in the treatment or prevention of blastic plasmacytoid dendritic cell neoplasms (BPDCN) or inflammatory diseases, in particular autoimmune diseases, involving plasmacytoid dendritic cells.

Abstract: The invention relates to chimeric or humanised anti-CD303 antibodies to nucleic acids coding for the heavy and light chains of these antibodies, expression vectors, host cells, transgenic non-human animals or transgenic plants expressing said antibodies, as well as to the uses thereof in the treatment or prevention of blastic plasmacytoid dendritic cell neoplasms (BPDCN) or inflammatory diseases, in particular autoimmune diseases, involving plasmacytoid dendritic cells.

Abstract: Disclosed is a pharmaceutical composition including, in a pharmaceutically acceptable carrier: at least one anti-CD303 antibody; and at least one anti-AMHRII antibody. Also disclosed is the combination of the two aforementioned antibodies a) and b) to form a combination product to be used simultaneously, separately or spread out over a period of time, for the prevention or treatment of urogenital cancers. Also disclosed is a method for preventing or treating an urogenital cancer in a subject in need thereof, such method including administering to the subject products containing: at least one anti-CD303 antibody; and at least one anti-AMHRII antibody.

Abstract: Disclosed is a pharmaceutical composition including, in a pharmaceutically acceptable carrier: a) at least one anti-CD303 antibody; and b) at least one anti-HER2 antibody. Also disclosed is the combination of the two aforementioned antibodies a) and b) to form combination products to be used simultaneously, separately or spread out over a period of time, for the prevention or treatment of HER2-positive cancer.

Abstract: The invention relates to a cell line expressing the gamma chain of the Fc?RI receptor and human CD303 antigen, characterized in that said cell line is transfected in a stable manner by an expression vector comprising a nucleic acid molecule coding for human CD303 antigen and having strong expression of human CD303 on the surface thereof, e.g. at least 10000 molecules of human CD303 per cell, as well as a vector or vector kit that can be used to co-express the gamma chain of the Fc?RI receptor and human CD303 antigen, and different uses of the cell line of the invention.

Abstract: Disclosed is an anti-CD303 protein antibody for use in the prophylaxis or therapy of a tumor, involving plasmacytoid dendritic cell activation in the environment of the tumor, said plasmacytoid dendritic cells not being the cause of the tumor.

Abstract: The invention relates to chimeric or humanised anti-CD303 antibodies to nucleic acids coding for the heavy and light chains of these antibodies, expression vectors, host cells, transgenic non-human animals or transgenic plants expressing said antibodies, as well as to the uses thereof in the treatment or prevention of blastic plasmacytoid dendritic cell neoplasms (BPDCN) or inflammatory diseases, in particular autoimmune diseases, involving plasmacytoid dendritic cells.

Abstract: The invention relates to a cell line expressing the gamma chain of the Fc?RI receptor and human CD303 antigen, characterised in that said cell line is transfected in a stable manner by an expression vector comprising a nucleic acid molecule coding for human CD303 antigen and having strong expression of human CD303 on the surface thereof, e.g. at least 10000 molecules of human CD303 per cell, as well as a vector or vector kit that can be used to co-express the gamma chain of the Fc?RI receptor and human CD303 antigen, and different uses of the cell line of the invention.

Abstract: Nucleic acids encoding various monocyte-derived proteins and related compositions, including purified proteins and specific antibodies are described. Methods of using such composition are also provided.

Abstract: An antibody directed against the BDCA-2 protein for the prevention or the treatment of the pathologies involving activation of the plasmacytoid dendritic cells.

Abstract: Nucleic acids encoding various monocyte-derived proteins and related compositions, including purified proteins and specific antibodies are described. Methods of using such composition are also provided.

Abstract: Nucleic acids encoding various monocyte-derived proteins and related compositions, including purified proteins and specific antibodies are described. Methods of using such composition are also provided.

Abstract: A bolus that is intended to be irradiated during radiotherapy. Advantageously, the bolus is made from a polyurethane gel.

Abstract: Nucleic acids encoding various monocyte-derived proteins and related compositions, including purified proteins and specific antibodies are described. Methods of using such composition are also provided.

Abstract: Nucleic acids encoding various monocyte-derived proteins and related compositions, including purified proteins and specific antibodies are described. Methods of using such composition are also provided.

Abstract: Nucleic acids encoding various monocyte-derived proteins and related compositions, including purified proteins and specific antibodies are described. Methods of using such composition are also provided.

Abstract: Nucleic acids encoding various monocyte-derived proteins and related compositions, including purified proteins and specific antibodies are described. Methods of using such composition are also provided.

Abstract: Kit of parts for treating a malignant pathology, an auto-immune disease or an infectious disease, comprising an effector cell which expresses the Fc?RIII receptor (CD16) on its surface, and a monoclonal antibody, the affinity of the Fc region of said monoclonal antibody for CD16 being greater than the affinity of the Fc region of the polyclonal immunoglobulins for CD16.

Abstract: A bolus that is intended to be irradiated during radiotherapy. Advantageously, the bolus is made from a polyurethane gel.

Abstract: The present invention relates to the use of an antibodies composition, the fucose content of which is less than 65%, for indicating apoptosis in vitro.